JP2019536782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536782A5 JP2019536782A5 JP2019528478A JP2019528478A JP2019536782A5 JP 2019536782 A5 JP2019536782 A5 JP 2019536782A5 JP 2019528478 A JP2019528478 A JP 2019528478A JP 2019528478 A JP2019528478 A JP 2019528478A JP 2019536782 A5 JP2019536782 A5 JP 2019536782A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- composition according
- composition
- sequence encoding
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 102100024108 Dystrophin Human genes 0.000 claims description 17
- 201000006938 muscular dystrophy Diseases 0.000 claims description 17
- 108010069091 Dystrophin Proteins 0.000 claims description 16
- 108020005004 Guide RNA Proteins 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 102000001039 Dystrophin Human genes 0.000 claims description 15
- 210000000663 muscle cell Anatomy 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 10
- 239000013607 AAV vector Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108010051583 Ventricular Myosins Proteins 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 3
- 101710158332 Diuretic hormone Proteins 0.000 claims description 3
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims description 3
- 101000987816 Triticum aestivum 16.9 kDa class I heat shock protein 1 Proteins 0.000 claims description 3
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 claims description 3
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 108010065781 myosin light chain 2 Proteins 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 241000604451 Acidaminococcus Species 0.000 claims description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 108700024394 Exon Proteins 0.000 claims description 2
- 241001112693 Lachnospiraceae Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000012224 gene deletion Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 239000003550 marker Substances 0.000 description 6
- 210000001087 myotubule Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 101150015424 dmd gene Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426853P | 2016-11-28 | 2016-11-28 | |
| US62/426,853 | 2016-11-28 | ||
| PCT/US2017/063468 WO2018098480A1 (en) | 2016-11-28 | 2017-11-28 | Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536782A JP2019536782A (ja) | 2019-12-19 |
| JP2019536782A5 true JP2019536782A5 (enExample) | 2021-01-14 |
Family
ID=60703123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528478A Pending JP2019536782A (ja) | 2016-11-28 | 2017-11-28 | ＣＲＩＳＰＲ／Ｃｐｆ１媒介性遺伝子編集による筋ジストロフィーの予防 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200046854A1 (enExample) |
| EP (1) | EP3545090A1 (enExample) |
| JP (1) | JP2019536782A (enExample) |
| CN (1) | CN110382695A (enExample) |
| AU (1) | AU2017364106A1 (enExample) |
| CA (1) | CA3044531A1 (enExample) |
| MX (1) | MX2019006157A (enExample) |
| WO (1) | WO2018098480A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2020225754A1 (en) * | 2019-05-06 | 2020-11-12 | Mcmullen Tara | Crispr gene editing for autosomal dominant diseases |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| CN110892069B (zh) * | 2017-03-30 | 2024-02-09 | 国立大学法人京都大学 | 基于基因组编辑的外显子跳跃诱导方法 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020122104A1 (ja) * | 2018-12-11 | 2020-06-18 | 国立大学法人京都大学 | ゲノムｄｎａに欠失を誘導する方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US20220145305A1 (en) * | 2019-02-12 | 2022-05-12 | Universita' Degli Studi Di Trento | CAS12a GUIDE RNA MOLECULES AND USES THEREOF |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| JP7881154B2 (ja) * | 2019-04-12 | 2026-06-29 | デューク ユニバーシティ | ジストロフィン機能を修復するためのＣＲＩＳＰＲ／Ｃａｓをベースにした塩基編集組成物 |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110499333A (zh) * | 2019-08-01 | 2019-11-26 | 广州德赫生物科技有限公司 | 用于修复dmd基因突变的核酸序列及系统 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021178474A1 (en) * | 2020-03-04 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | A rodent model of b4galt1-mediated functions |
| US20240287486A1 (en) * | 2020-04-24 | 2024-08-29 | University Of Massachusetts | Improved cas 12a/nls mediated therapeutic gene editing platforms |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| EP4149622A4 (en) * | 2020-05-12 | 2024-12-18 | Myogene Bio LLC | IMMUNOSUPPRESSIVE AGENTS AND METHODS OF RE-DOSING VIRAL ADMINISTRATION FOR GENE THERAPY |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN116529365A (zh) * | 2020-09-09 | 2023-08-01 | 弗特克斯药品有限公司 | 用于治疗杜氏肌营养不良的组合物和方法 |
| US20220096606A1 (en) * | 2020-09-09 | 2022-03-31 | Vertex Pharmaceuticals Incorporated | Compositions and Methods for Treatment of Duchenne Muscular Dystrophy |
| WO2022140340A1 (en) * | 2020-12-22 | 2022-06-30 | Vertex Pharmaceuticals Incorporated | Compositions comprising an rna guide targeting dmd and uses thereof |
| WO2022251181A1 (en) * | 2021-05-25 | 2022-12-01 | The Board Of Regents Of The University Of Texas System | Correction of duchenne muscular dystrophy mutations with all-in-one adeno-associated virus-delivered single-cut crispr |
| CN118591391A (zh) * | 2021-07-09 | 2024-09-03 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CN114214360A (zh) * | 2021-12-27 | 2022-03-22 | 西安英创生物技术有限公司 | 先天性肌无力小鼠模型、其构建方法及应用 |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| TW202345911A (zh) * | 2022-03-08 | 2023-12-01 | 美商維泰克斯製藥公司 | 用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| CN120648680A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的药物 |
| CN118086408A (zh) * | 2024-04-25 | 2024-05-28 | 华南理工大学 | 一种可实现靶向肌肉细胞基因编辑的仿病毒颗粒及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK99653C (da) | 1959-06-24 | 1964-08-31 | Skaanska Aettikfabriken Ab | Pynteliste til brug som sammenfojningsliste, hjørneliste eller endeliste ved montering af beklædningsplader. |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| EP3133160B1 (en) * | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| HK1220154A1 (zh) * | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| WO2014197748A2 (en) * | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| AU2015229299A1 (en) * | 2014-03-12 | 2016-09-22 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| CA2957932A1 (en) * | 2014-08-11 | 2016-02-18 | The Board Of Trustees Of The University Of Illinois | Devices and related methods for epidermal characterization of biofluids |
| US20160058889A1 (en) * | 2014-08-11 | 2016-03-03 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by crispr/cas9-mediated gene editing |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| KR20240132120A (ko) * | 2015-08-25 | 2024-09-02 | 듀크 유니버시티 | Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법 |
| EP3332008A4 (en) * | 2015-09-23 | 2019-01-16 | Université Laval | CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF |
| EP4279084B1 (en) * | 2015-10-28 | 2025-06-11 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
| JP7490211B2 (ja) * | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
-
2017
- 2017-11-28 AU AU2017364106A patent/AU2017364106A1/en not_active Abandoned
- 2017-11-28 EP EP17817498.3A patent/EP3545090A1/en not_active Withdrawn
- 2017-11-28 US US16/464,124 patent/US20200046854A1/en not_active Abandoned
- 2017-11-28 WO PCT/US2017/063468 patent/WO2018098480A1/en not_active Ceased
- 2017-11-28 JP JP2019528478A patent/JP2019536782A/ja active Pending
- 2017-11-28 MX MX2019006157A patent/MX2019006157A/es unknown
- 2017-11-28 CA CA3044531A patent/CA3044531A1/en not_active Abandoned
- 2017-11-28 CN CN201780084906.8A patent/CN110382695A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7822933B2 (ja) | マイクロジストロフィン遺伝子治療コンストラクト及びその使用 | |
| JP2020503869A5 (enExample) | ||
| CN109069672B (zh) | 腺相关病毒载体传递微肌营养不良蛋白以治疗肌营养不良症 | |
| ES2535877T3 (es) | Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica | |
| JP2020513811A5 (enExample) | ||
| EP2933335A1 (en) | A method of treating peripheral neuropathies and motor neuron diseases | |
| JPWO2014103957A1 (ja) | Ａａｖ変異体 | |
| AU2016355343A1 (en) | Compositions and methods for correction of heritable ocular disease | |
| JP2020513831A (ja) | ＭｅＣＰ２発現カセット | |
| JP2024159800A (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| CN119137273A (zh) | 包括工程化核内小RNA（snRNA）的组合物和方法 | |
| ES3057171T3 (en) | Peptide-modified aav capsid with enhanced muscle transduction efficiency | |
| JP7671790B2 (ja) | 眼疾患の遺伝子治療 | |
| JP2024054398A (ja) | 糖原病ｉｉｉの処置のためのミニｇｄｅ | |
| JP2025093922A (ja) | Ｃｌｎ６ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| JP2025534666A (ja) | 操作された核酸調節エレメントならびにその使用方法 | |
| JP2022519596A (ja) | Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達 | |
| US20250230443A1 (en) | Products and methods for inhibition of expression of dynamin-1 variants | |
| TW202449145A (zh) | 具有改良負載基因表現率及降低基因毒性之腺相關病毒之經修飾複合體平台 | |
| CN115605266A (zh) | Dysferlin双载体的基因疗法 | |
| AU2020366242A1 (en) | Materials and methods for the treatment of disorders associated mutations in the IRF2BPL gene | |
| AU2020385387A1 (en) | Materials and methods for treatment of disorders associated with the IGHMBP2 gene | |
| WO2025232917A1 (en) | Novel liver detargeted aav variants and uses thereof | |
| CA3299376A1 (en) | Brain-tropic aav mutant | |
| WO2026094009A1 (en) | Compositions and methods for treating duchenne muscular dystrophy |